choline-fenofibrate

Description: Choline fenofibrate (formerly also known as ABT-335 or choline salt of fenofibric acid) is a novel, synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity that acts as an PPARalpha agonist. It was under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. It is a lipid regulating agent available as delayed release capsules for oral administration. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor alpha (PPARalpha). Through this mechanism, fenofibric acid increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of Apo CIII (an inhibitor of lipoprotein lipase activity). Activation of PPARalpha also induces an increase in the synthesis of HDL-C and Apo AI and AII.

References: Clin Drug Investig. 2008; 28(10):625-34.